Encapsulation structure with the ability to prevent the degradation of bioactive substances and to enable a long-term effect of these bioactive substances

Abstract

A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a variety of encapsulation structure bodies (10), characterized by that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

Description

Technical field

[0001] The invention relates to an encapsulation structure, in particular an encapsulation structure that can prevent the degradation of bioactive substances, so that the bioactive substances can have a lasting effect. State of the art

[0002] Bioactive substances play an important role in foods and dietary supplements, but their stability and the control of their release over long periods are frequently questioned. Bioactive substances are easily oxidized, leading to a loss of activity, or they are rapidly eliminated from the bloodstream, impairing their effectiveness. Current technologies have not yet provided effective solutions to these problems. Object of the invention

[0003] The invention is based on the objective of creating a long-lasting encapsulation structure with the ability to prevent the degradation of bioactive substances, thus avoiding the disadvantages associated with the prior art. Technical solution

[0004] This problem is solved according to the invention by a persistent encapsulation structure with the ability to prevent the degradation of bioactive substances, having the features of claim 1. Advantageous embodiments are the subject of the dependent claims.

[0005] The invention provides a persistent encapsulation structure capable of preventing the degradation of bioactive substances. This encapsulation structure comprises a plurality of encapsulation structure bodies, each encapsulating a polysaccharide structure in which a plurality of bioactive substances are encapsulated. The bioactive substance is selected from a group consisting of a bioactive fatty substance and a bioactive non-fatty substance. The polysaccharide structure comprises at least one polysaccharide. The at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed, and finally atomized and dried, resulting in a polysaccharide structure consisting of branched and linear polysaccharides that form a plurality of staggered network structures.The bioactive fatty substance is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterol, and fatty acid substances. The bioactive non-fatty substance is selected from a group consisting of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids, and their derivatives.

[0006] The persistent encapsulation structure according to the invention, which is capable of preventing the degradation of bioactive substances, is characterized by the following: The polysaccharide structure forms branched and linear polysaccharides, which, due to their different lengths, create a multitude of staggered network structures. This effectively prevents degradation, allowing the polysaccharide structure to protect the bioactive substances and prevent damage to their composition and nutrients from external influences. Because the bioactive substances are encapsulated by the polysaccharide structure, a certain amount of space is created, which slows down the degradation of the bioactive substances. This extends or increases the duration of action and the concentration of the bioactive substances in the human body, thus achieving a long-lasting effect. Brief description of the drawings Fig. Figure 1 shows a perspective view of a persistent encapsulation structure according to the invention with the ability to prevent the degradation of bioactive substances. Fig. Figure 2 shows a schematic representation of an encapsulation structure body of the encapsulation structure according to the invention. Fig. Figure 3 shows an enlarged view of a section of the encapsulation structure body in Fig. 2. Fig. Figure 4 shows a first schematic representation of a test comparison of the degradation of bioactive substances according to the invention. Fig. Figure 5 shows a second schematic representation of a test comparison of the degradation of bioactive substances according to the invention. Fig. Figure 6 shows a third schematic representation of a test comparison of the degradation of bioactive substances according to the invention. Fig. Figure 7 shows a fourth schematic representation of a test comparison of the degradation of bioactive substances according to the invention. Fig. Figure 8 shows a fifth schematic representation of a test comparison of the degradation of bioactive substances according to the invention. Fig. Figure 9 shows a schematic representation of a test comparison of the degradation of bioactive substances according to the invention. Detailed description of a preferred embodiment

[0007] The following section will explain in more detail the tasks, features, and advantages of the present invention with reference to a detailed description of an exemplary embodiment and the accompanying drawings. However, the invention is not limited to the description of this exemplary embodiment and its illustration in the accompanying drawings.

[0008] As in Fig. 1 to Fig. As shown in Figure 3, the invention relates to a persistent encapsulation structure with the ability to prevent the degradation of bioactive substances, which encapsulation structure comprises a plurality of encapsulation structure bodies 10, wherein each encapsulation structure body 10 has a polysaccharide structure 11 in which a plurality of bioactive substances 12 are encapsulated, wherein the bioactive substance 12 is selected from a group consisting of a bioactive fatty substance 121 and a bioactive non-fatty substance 122.

[0009] The polysaccharide structure 11 comprises at least one polysaccharide. The at least one polysaccharide is first thoroughly mixed, then sheared under high pressure or homogenized at high speed, and finally atomized and dried, so that the polysaccharide structure 11 forms branched polysaccharides and linear polysaccharides that form a multitude of staggered network structures.

[0010] The bioactive fatty substance 121 is selected from a group of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances.

[0011] The bioactive non-fatty substance 122 is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives.

[0012] According to the invention, the polysaccharide structure 11 forms branched and linear polysaccharides which, due to their different lengths, create a multitude of staggered network structures that effectively prevent degradation. This allows the polysaccharide structure 11 to effectively protect the bioactive substances 12, preventing damage to their composition and nutrients from external influences (e.g., water, oxygen, temperature, and pH). The encapsulation of the bioactive substances 12 by the polysaccharide structure 11 creates a space that slows down their degradation, thus extending or increasing their duration of action and concentration in the human body to achieve a long-lasting effect.

[0013] Thus, the encapsulation structures 10 effectively solve the problem of the bioactive substances 12 oxidizing and being rapidly excreted from the blood. The polysaccharide structure 11 ensures both increased stability of the bioactive substances 12 and optimal long-term efficacy, giving the polysaccharide structure 11 great potential for broad application.

[0014] In the persistent encapsulation structure according to the invention, which has the ability to prevent the degradation of bioactive substances, the polysaccharide structure 11 can be made of dietary fiber. Regarding the selection of the bioactive fatty substances 121, the fatty acid substances can be natural vegetable oils / fats, animal oils / fats, or algal oils with short-, medium-, or long-chain fatty acids. Regarding the selection of the bioactive non-fatty substances 122, the coenzymes Q10 and NAD can be used. + , NADP +, NADH, NADPH, NMN, FAD or FMN, the polyphenols can be flavonoids, proanthocyanidins, phenolic acids, lignans or stilbenes, the acid substances can be sialic acid, lipoic acid, lactic acid, malic acid, aldonic acid or keto acid, the carbohydrates can be glucans, polysaccharides, oligosaccharides, glycoproteins, proteoglycans or mucopolysaccharides.

[0015] The material for the polysaccharide structure 11 can be dietary fiber, starch, dextrin, indigestible maltodextrin, plant colloids, chitin, modified starch, natural or synthetic cellulose, but the material is not limited to those listed.

[0016] For the comparison of the degradation of the bioactive substances 12, which are proanthocyanidins, polyphenols and anthocyanins, in a simulated gastric acid with a pH of 2 for three hours, the following is used: Fig. 4 to Fig. 6 referred to. For the comparison of the accelerated experiments of the bioactive substances 12, which are short-chain fatty acids, digestive enzymes and polyunsaturated fatty acids, under the conditions 40±2°C and 75±5%RH, reference is made to Fig. 7 to Fig. 9. It is clearly evident that the bioactive substances 12 encapsulated by the polysaccharide structure 11 are degraded much more slowly.

[0017] Although the present invention has been described in detail with reference to an exemplary embodiment, it is obvious to those skilled in the art that the invention is not limited to this embodiment, but rather that modifications are possible such that individual features can be omitted or different combinations of features can be implemented, as long as the scope of protection of the appended claims is not exceeded. The disclosure of the present invention includes all combinations of the individual features presented. Reference symbol list 10 encapsulation structure bodies 11 Polysaccharide structure 12 bioactive substances 121 bioactive fatty substance 122 bioactive non-fat substances

Claims

[1] A persistent encapsulation structure capable of preventing the degradation of bioactive substances, which encapsulation structure comprises a multitude of encapsulation structure bodies (10), characterized by , that the respective encapsulation structure body (10) has a polysaccharide structure (11) by which a plurality of bioactive substances (12) are encapsulated, wherein the bioactive substance (12) is selected from a group consisting of a bioactive fatty substance (121) and a bioactive non-fatty substance (122); that the polysaccharide structure (11) comprises at least one polysaccharide, wherein the at least one polysaccharide is first thoroughly mixed, then sheared at high pressure or homogenized at high speed and finally atomized dried, such that the polysaccharide structure (11) forms branched polysaccharides and linear polysaccharides which form a multitude of network structures; that the bioactive fatty substance (121) is selected from a group consisting of glycerophospholipids, sphingophospholipids, gangliosides, L-α- / glycerylphosphorylcholines, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositol, phosphatidylserines, phosphatidic acids, phosphatidylglycerol, ceramides, glucocerebrosides, glycolipids, cholesterols and fatty acid substances; and that the bioactive nonfatty substance (122) is selected from a group of coenzymes, vitamins, carotenes, carotenoids, curcuminoids, curcumin, curcumin extract, polyphenols, saponins, glycosides, terpenoids, ergothioneine, minerals, acid substances, functional polysaccharides, carbohydrates, functional proteins, peptides, amino acids and their derivatives. [2] Encapsulation structure according to claim 1, characterized by , that dietary fiber can be used as material for the polysaccharide structure (11). [3] Encapsulation structure according to claim 1, characterized by, that the material of the polysaccharide structure (11) can be dietary fiber, starch, dextrin, indigestible maltodextrin, plant colloids, chitin, modified starch, natural or synthetic cellulose. [4] Encapsulation structure according to claim 1, characterized by , that when selecting the material of the bioactive fatty substances (121) the fatty acid substances may be natural vegetable oils / fats, animal oils / fats or algal oils with short-, medium- or long-chain fatty acids. [5] Encapsulation structure according to claim 1, characterized by , that when selecting the material of the bioactive non-fat substances (122) the coenzymes Q10, NAD + , NADP +, NADH, NADPH, NMN, FAD or FMN, the polyphenols can be flavonoids, proanthocyanidins, phenolic acids, lignans or stilbenes, the acid substances can be sialic acid, lipoic acid, lactic acid, malic acid, aldonic acid or keto acid, and the carbohydrates can be glucans, polysaccharides, oligosaccharides, glycoproteins, proteoglycans or mucopolysaccharides.

Images